journal
MENU ▼
Read by QxMD icon Read
search

Lupus Science & Medicine

journal
https://www.readbyqxmd.com/read/30515297/similar-dysregulation-of-lupus-associated-mirnas-in-peripheral-blood-mononuclear-cells-and-splenic-lymphocytes-in-mrl-lpr-mice
#1
Zhuang Wang, Bettina Heid, Rujuan Dai, Sattar Ansar Ahmed
Objective: MicroRNAs (miRNAs) play an important role in the pathogenesis of various autoimmune diseases including systemic lupus erythematosus (SLE; lupus). We have previously reported a common pattern of miRNA dysregulation in splenic lymphocytes from several mouse models of lupus. In this study, we investigated whether there is a similar miRNAs expression dysregulation in peripheral blood mononuclear cells (PBMCs) and splenocytes in a classical murine lupus model, MRL/lpr. Method: PBMCs were isolated from blood samples of control MRL and lupus MRL/lpr mice aged 14-15 weeks by gradient centrifugation with Histopaque 1083 density media...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30397499/correction-patient-reported-outcome-measures-for-use-in-clinical-trials-of-sle-a-review
#2
(no author information available yet)
[This corrects the article DOI: 10.1136/lupus-2018-000279.].
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30397498/cytoplasmic-foxo1-identifies-a-novel-disease-activity-associated-b-cell-phenotype-in-sle
#3
Molly K Hritzo Ahye, Amit Golding
Systemic lupus erythematosus (SLE) is a manifestation of hyperactivated lymphocytes and results, in part, from the loss of normal tolerance checkpoints. FOXO1 is a transcription factor involved at critical early and late B cell development checkpoints; however, its role in regulating peripheral B cell tolerance is not fully understood. We have applied our published approach for using imaging flow cytometry to study native FOXO1 localisation in human lymphocytes to peripheral blood samples from healthy individuals versus patients with SLE...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30397497/alopecias-in-lupus-erythematosus
#4
Josef Symon Salgado Concha, Victoria P Werth
Several patterns of hair loss can occur in lupus erythematosus (LE). Alopecias which show histological characteristics of LE are LE-specific, and include discoid LE (DLE), diffuse or patchy hair loss in acute LE, subacute cutaneous LE, and rarely tumid LE. Lupus hair in SLE is a poorly characterised entity and may be a form of telogen effluvium. Alopecia areata can coexist with LE and may mimic DLE. Non-lupus alopecias such as telogen effluvium and anagen effluvium have a myriad of causes which include disease flares, drugs and stress in the setting of LE...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30397496/elevation-of-serum-anti-glucose-regulated-protein-78-antibodies-in-neuropsychiatric-systemic-lupus-erythematosus
#5
Yu Matsueda, Yoshiyuki Arinuma, Tatsuo Nagai, Shunsei Hirohata
Objective: Recent studies have demonstrated that autoantibodies directed against glucose-regulated protein 78 (GRP78) on endothelial cells promote blood-brain barrier (BBB) damages. The present study examined whether serum anti-GRP78 antibodies might be involved in the pathogenesis of neuropsychiatric SLE (NPSLE). Methods: Serum samples were obtained from 129 patients with SLE (58 patients with diffuse psychiatric/neuropsychological syndromes of NPSLE (diffuse NPSLE), 30 with neurological syndromes (focal NPSLE), 21 with lupus nephritis (LN), 20 without NPSLE or LN (SLE alone)), from 35 patients with non-SLE rheumatic diseases (non-SLE RD) and from 24 healthy controls (HC)...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30397495/analysis-of-urinary-macrophage-migration-inhibitory-factor-in-systemic-lupus-erythematosus
#6
Fabien B Vincent, Laura Slavin, Alberta Y Hoi, Arthur Richard Kitching, Fabienne Mackay, James Harris, Rangi Kandane-Rathnayake, Eric F Morand
Objective: To characterise the clinical relevance of urinary macrophage migration inhibitory factor (uMIF) concentrations in patients with systemic lupus erythematosus (SLE). Methods: MIF, adjusted for urine creatinine, was quantified by ELISA in urine samples from 64 prospectively recruited patients with SLE. Serum MIF and urinary monocyte chemoattractant protein 1 (uMCP-1) were quantified by ELISA in a subset of patients (n = 39). Disease activity was assessed using the SLE Disease Activity Index-2000 (SLEDAI-2K) score...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30364418/obstetric-antiphospholipid-syndrome
#7
REVIEW
Aleksandra Antovic, Maria Sennström, Katarina Bremme, Elisabet Svenungsson
The present clinical and laboratory classification criteria for antiphospholipid syndrome (APS) were established in Sydney, Australia, in 2006. In this review, we focus on the obstetric subset of APS (OAPS), defined by persistent positivity for antiphospholipid antibodies together with either early recurrent pregnancy loss, early fetal death, stillbirth or premature birth <34 gestational weeks due to pre-eclampsia, eclampsia and placental insufficiency. It is important to diagnose these cases since most women suffering from OAPS can, when given appropriate treatment, have successful pregnancies...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30319781/evaluating-duration-of-response-to-treatment-in-systemic-lupus-erythematosus-clinical-trials
#8
Mimi Kim, Joan T Merrill, Kenneth Kalunian, Leslie Hanrahan, Peter Izmirly
Objective: To evaluate response duration and identify predictors of transitioning into and out of the response state in patients with SLE receiving standard of care (SoC) in 52-week clinical trials. Methods: A multistate model (MSM) allowing for bidirectional transitions between response and non-response states was fit to data on 759 patients with SLE with active disease randomised to SoC. The probability of being in response at 52 weeks, average duration of response (sojourn time) and mean total time in response for SLE Responder Index (SRI-4, SRI-5, SRI-6) and BILAG-based Composite Lupus Assessment (BICLA) were estimated...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30305912/increased-alloreactive-and-autoreactive-antihuman-leucocyte-antigen-antibodies-associated-with-systemic-lupus-erythematosus-and-rheumatoid-arthritis
#9
Rachael P Jackman, Giovanna I Cruz, Joanne Nititham, Darrell J Triulzi, Lisa F Barcellos, Lindsey A Criswell, Philip J Norris, Michael P Busch
Objectives: Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) disproportionately affect women during and following childbearing years. Antihuman leucocyte antigen (HLA) alloantibody responses are common in healthy parous women, and as these diseases are both linked with HLA and immune dysregulation, we sought to evaluate anti-HLA antibodies in RA and SLE. Methods: Anti-HLA antibodies were measured among parous SLE cases (n=224), parous RA cases (n=202) and healthy parous controls (n=239) and compared with each other as well as with nulliparous female and male controls...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30233806/serum-albumin-at-1-year-predicts-long-term-renal-outcome-in-lupus-nephritis
#10
Vinicius Domingues, Benjamin A Levinson, Nicole Bornkamp, Judith D Goldberg, Jill Buyon, H Michael Belmont
Objectives: The study aimed to determine if serum albumin at 12 months predicts long-term renal outcome at 48 months. Data from the NYU SAMPLE (Specimen and Matched Phenotype Linked Evaluation) Lupus Registry were used to compare the performance of albumin, anti-double-stranded DNA, C3/C4, proteinuria and haematuria. Methods: 82 patients with SLE with data at time of renal biopsy, at 12 months and at a second visit, and up to 48 months were included. The significance of each biomarker as a predictor of an adverse renal outcome (ARO), defined as doubling of serum creatinine, as creatinine >4 mg/dL if initial >2...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30233083/correction-report-of-the-inaugural-interferon-research-summit-interferon-in-inflammatory-diseases
#11
(no author information available yet)
[This corrects the article DOI: 10.1136/lupus-2018-000276.].
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30167316/transition-and-transfer-of-the-patient-with-paediatric-onset-lupus-a-practical-approach-for-paediatric-and-adult-rheumatology-practices
#12
Rebecca E Sadun, Laura E Schanberg
The prevalence of paediatric-onset SLE (pSLE) is estimated at 1million people worldwide and accounts for a significant proportion of SLE morbidity, mortality and cost. Patients with pSLE are especially vulnerable during and immediately following transfer from paediatric to adult rheumatology care, when substantial delays in care and increased disease activity are common. Transition is the process through which adolescents and young adults (AYA) develop the skills needed to succeed in the adult healthcare environment, a process that typically takes several years and may span a patient's time in paediatric and adult clinics...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30167315/patient-reported-outcome-measures-for-use-in-clinical-trials-of-sle-a-review
#13
Zara Izadi, Julie Gandrup, Patricia P Katz, Jinoos Yazdany
Inclusion of patient-reported outcomes is important in SLE clinical trials as they allow capture of the benefits of a proposed intervention in areas deemed pertinent by patients. We aimed to compare the measurement properties of health-related quality of life (HRQoL) measures used in adults with SLE and to evaluate their responsiveness to interventions in randomised controlled trials (RCTs). A systematic review was undertaken using full original papers in English identified from three databases: MEDLINE, EMBASE and PubMed...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30167314/qrisk3-improves-detection-of-cardiovascular-disease-risk-in-patients-with-systemic-lupus-erythematosus
#14
Nicola Edwards, Alexander W W Langford-Smith, Benjamin J Parker, Ian N Bruce, John A Reynolds, M Yvonne Alexander, Eoghan M McCarthy, Fiona L Wilkinson
Objective: 10-year cardiovascular disease (CVD) risk scores are calculated using algorithms, including Framingham (worldwide) and QRISK2 (UK). Recently, an updated QRISK3 model was introduced, which considers new variables including SLE and steroid prescription, not included in QRISK2 and Framingham algorithms. We sought to determine the extent to which QRISK3 improves identification of high-risk patients with SLE and whether the score relates to standard and novel markers of SLE-specific endothelial dysfunction...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30117502/correction-dysregulation-of-mirnas-expression-levels-and-disease-activity-in-sle-patients
#15
(no author information available yet)
[This corrects the article DOI: 10.1136/lupus-2017-000215.317.][This corrects the article DOI: 10.1136/lupus-2017-000215.317.].
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30094041/dna-methylation-101-what-is-important-to-know-about-dna-methylation-and-its-role-in-sle-risk-and-disease-heterogeneity
#16
Cristina M Lanata, Sharon A Chung, Lindsey A Criswell
SLE is a complex autoimmune disease that results from the interplay of genetics, epigenetics and environmental exposures. DNA methylation is an epigenetic mechanism that regulates gene expression and tissue differentiation. Among all the epigenetic modifications, DNA methylation perturbations have been the most widely studied in SLE. It mediates processes relevant to SLE, including lymphocyte development, X-chromosome inactivation and the suppression of endogenous retroviruses. The establishment of most DNA methylation marks occurs in utero; however, a small percentage of epigenetic marks are dynamic and can change throughout a person's lifetime and in relation to exposures...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30094040/myocarditis-in-systemic-lupus-erythematosus-diagnosed-by-18-f-fluorodeoxyglucose-positron-emission-tomography
#17
Alexandra Perel-Winkler, Sabahat Bokhari, Thania Perez-Recio, Afshin Zartoshti, Anca Askanase, Laura Geraldino-Pardilla
Objectives: Cardiovascular diseaseand heart failure (CHF) are leading causes of death in systemic lupus erythematosus (SLE). The underlying mechanisms for increased CHF in SLE are unclear but myocardial inflammation and lupus myocarditis (LM) may play a role. We propose that 18 F-fluorodeoxyglucose-positron emission tomography (18 F-FDG-PET)/CT can help diagnose LM. Methods: This report describes eight patients with presumed LM; five patients were evaluated due to active cardiorespiratory symptoms and three patients were participating in a pilot study to determine the prevalence of subclinical myocarditis in SLE...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/30094039/measuring-lupus-arthritis-activity-using-contrasted-high-field-mri-associations-with-clinical-measures-of-disease-activity-and-novel-patterns-of-disease
#18
Eric S Zollars, Madison Hyer, Bethany Wolf, Russell Chapin
Objective: Arthritis in SLE is poorly described, and there is no objective measure for quantification of arthritis. In this pilot study, we aim to assess the utility of the Rheumatoid Arthritis MRI Scoring System (RAMRIS) for the quantification of lupus arthritis. Methods: Patients were eligible for entry into the study if they were evaluated at the Medical University of South Carolina Lupus Center and determined by their treating rheumatologist to have active hand arthritis due to SLE...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/29955371/correction-lupus-community-panel-proposals-for-optimising-clinical-trials-2018
#19
(no author information available yet)
[This corrects the article DOI: 10.1136/lupus-2018-000258.].
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/29955370/tnf-%C3%AE-and-plasma-albumin-as-biomarkers-of-disease-activity-in-systemic-lupus-erythematosus
#20
Helena Idborg, Susanna Eketjäll, Susanne Pettersson, Johanna T Gustafsson, Agneta Zickert, Marika Kvarnström, Vilija Oke, Per-Johan Jakobsson, Iva Gunnarsson, Elisabet Svenungsson
Objectives: Composite criteria/indices are presently used to diagnose and monitor patients with systemic lupus erythematosus (SLE). Biomarkers for these purposes would be helpful in clinical practice. We therefore evaluated a large panel of cytokines and basic laboratory tests and investigated their performance as discriminators versus controls and as biomarkers of disease activity (DA). Methods: We examined 437 patients with SLE, fulfilling American College of Rheumatology-82 criteria, and 322 matched controls...
2018: Lupus Science & Medicine
journal
journal
49380
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"